IGC Pharma expects ‘continued strong momentum’ into 2H26

The company said,”IGC expects continued strong momentum heading into the second half of fiscal 2026, with key strategic priorities focused on pipeline execution and AI commercialization: Clinical Acceleration: Completing patient enrollment in the CALMA Phase 2 study. AI Monetization: Initiating key collaborations for piloting MINT-AD with academic and clinical partners. Pipeline Deepening: Advancing the promising IGC-M3 preclinical asset. Strategic Partnerships: Evaluating strategic partnerships across AI diagnostics and Alzheimer’s therapeutics. Financial Stewardship: Strengthening operational efficiency while preserving cash runway and financial flexibility.”